

# Lysosome Storage Disease Mouse Models



WuXi AppTec, WuXi Biology, Oncology & Immunology Unit



2023.06


## ■ Background

- Introduction of Lysosome Storage Disease (LSD)

## ■ Selected Showcases of Model Generation/Application for LSD

- MPS I mouse model
- Gaucher mouse model
- Pompe mouse model
- Fabry mouse model


# Introduction of Lysosome Storage Disease (LSD)



- Lysosomal storage diseases (LSDs) are a group of over 70 diseases that are characterized by lysosomal dysfunction, most of which are inherited as autosomal recessive traits.
- These disorders are individually rare but collectively affect 1 in 5,000 live births.
- The lysosome is the key cellular hub for macromolecule catabolism, recycling and signaling.
- LSD associated genes encode different lysosomal proteins, including lysosomal enzymes and lysosomal membrane proteins.
- Mutations in genes resulting in cellular damage can be associated with symptoms in specific organs.


Platt, F.M., et al. *Nat Rev Dis Primers* 4, 27 (2018)

# Molecular Pathways in LSDs






# MPS I Mouse Model Generation & Characterization




**Figure: (A)** Strategy for MPS I mouse model generation; **(B)** H&E staining of WT and MPS I mouse Kidney; **(C-D)** Tissue GAG content and *Idua* enzyme activity; **(E)** Open field test in WT and MPS I mice.

# Gaucher Mouse Model Generation & Characterization






**Figure: (A)** Strategy for *Gba* KO & KI (*Gba* mutation) mouse model generation; **(B)** Histopathology changes in Gaucher mouse liver; **(C-D)** Tissue GlcCer content and GCCase enzyme activity; **(E)** Open field test in WT and Gaucher mice.

# Application of Pompe Mouse Model




The Pompe mice were sourced from JAX (JAX 004154)



**Figure: (A)** Strategy for Pompe mouse model generation; **(B)** *Gaa* enzyme activity in tissue; **(C)** Glycogen staining in heart; **(D)** Forelimb strength test in WT, Pompe mice without or with enzyme replacement therapy (ERT) treatment.

# Application of Fabry Mouse Model



**Figure: (A)** Strategy for Fabry mouse model generation; **(B-C)** *Gla* enzyme activity and lyso-Gb3 content in liver; **(D)** IHC staining of *Gla* in kidney; **(E-F)** Open field and light-dark box test in Fabry mice without or with ERT treatment.





# OUR COMMITMENT

## *Improving Health. Making a Difference.*

For questions and requests, please email to [OIU-BD-Translation@wuxiapptec.com](mailto:OIU-BD-Translation@wuxiapptec.com)



<https://onco.wuxiapptec.com>